1. Home
  2. CURV vs IFRX Comparison

CURV vs IFRX Comparison

Compare CURV & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

N/A

Current Price

$2.23

Market Cap

253.3M

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.18

Market Cap

225.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CURV
IFRX
Founded
2001
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.3M
225.5M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
CURV
IFRX
Price
$2.23
$1.18
Analyst Decision
Hold
Strong Buy
Analyst Count
7
8
Target Price
$2.17
★ $8.41
AVG Volume (30 Days)
164.8K
★ 1.1M
Earning Date
12-02-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.06
N/A
Revenue
★ $1,000,092,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.63
N/A
P/E Ratio
$36.17
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.94
$0.80
52 Week High
$2.86
$2.95

Technical Indicators

Market Signals
Indicator
CURV
IFRX
Relative Strength Index (RSI) 47.69 28.81
Support Level $2.03 $0.81
Resistance Level $2.55 $2.44
Average True Range (ATR) 0.20 0.15
MACD -0.01 -0.03
Stochastic Oscillator 31.33 0.81

Price Performance

Historical Comparison
CURV
IFRX

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: